Biotech | January 21, 2022
Palleon announces IND clearance for first-in-class cancer immunotherapy
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
Phase 1/2 trial of E-602 expected to open in Q1 2022 in patients with solid tumours
In addition to its favourable activity profile, IBIO123 is formulated for administration by inhalation providing an efficient, rapid and non-invasive delivery method into the lungs via the respiratory tract
Innovative market development collaboration also signed, expanding the availability of select Novartis oncology products in regions across China currently not covered by Novartis
The Macau authorization followed a regulatory review that considered prior decisions by both the US FDA) and the European Medicines Agency
These approvals represent a defining moment for people living with classical Hodgkin Lymphoma
AstraZeneca says the approval strengthens its push to bring immunotherapy earlier into cancer treatment, where long-term cures are possible
The Phase 1 dose-escalation trial enrolled 25 evaluable patients and was designed to determine the recommended dose of LYMPHIR
Strong performances in its Life Science, Healthcare and Electronics divisions — particularly Process Solutions, Cardiovascular treatments and Semiconductor Materials — powered the company’s results
A next-generation, cell-based immunotherapy, CAR-T therapy engineers a patient’s own immune cells to detect and destroy cancer
Subscribe To Our Newsletter & Stay Updated
